M. Meyers

发表

Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

Sylvia Janetzki, Jonathan J. Lewis, Siqun Wang, 2000, International journal of cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety

P. Thall, F. Khuri, W. Hong, 2000 .

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Allelic loss and somatic differentiation in human male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1994, Oncogene.

Myasthenia gravis induced by avelumab.

B. Soliven, G. Fleming, K. Rezania, 2019, Immunotherapy.

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

A. Molina, M. Meyers, D. End, 2013, Cancer research.

Fast and flawed or scientifically sound: the argument for administering oral oncology drugs during fasting.

M. Acharya, A. Molina, M. Meyers, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

A. Jenkner, K. Norga, Martha Donoghue, 2020, European journal of cancer.

Medical treatment of metastatic melanoma.

A. Houghton, P. Chapman, M. Meyers, 1996, The Surgical clinics of North America.

The Origin of Non-Germ Cell Tumour Elements within Germ Cell Tumours and Midline Tumours of Uncertain Histogenesis

R. Motzer, R. Chaganti, G. Bosl, 1994 .

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

S. Armstrong, M. Rivera, K. Stegmaier, 2020, European journal of cancer.

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.

P. Jänne, E. Schmidt, S. Ramalingam, 2018 .

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.

P. Danaher, R. Sullivan, E. Schmidt, 2018 .

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

P. Jänne, E. Schmidt, S. Ramalingam, 2020, Clinical Cancer Research.

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

C. Begg, J. Kirkwood, A. Houghton, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma

C. Begg, J. Kirkwood, A. Houghton, 1999 .

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

E. Basch, C. Cleeland, C. Logothetis, 2013, The Lancet. Oncology.

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

J. Dipersio, I. Aldoss, M. Arellano, 2021, Blood.

Adjuvant therapy of malignant melanoma.

D. Coit, M. Dickler, M. Meyers, 1997, Surgical oncology clinics of North America.

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

L. Coussens, Z. DeFilipp, Stephanie J. Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

J. Dipersio, N. Shukla, I. Aldoss, 2022, Blood.

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, G. Hill, P. Ordentlich, 2020 .

ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

E. Schmidt, Melissa L. Johnson, Douglas B. Johnson, 2018 .

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

H. Hurwitz, S. Kaufmann, A. Adjei, 2011, Cancer investigation.

Metastatic germ cell tumors: modeling for response to chemotherapy.

R. Motzer, M. Mazumdar, D. Bajorin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors

A. Tolcher, Sunil Sharma, D. Rasco, 2020 .

Genetic variation associated with bortezomib-induced peripheral neuropathy

G. Mulligan, P. Richardson, R. Favis, 2011, Pharmacogenetics and genomics.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

S. Armstrong, J. Dipersio, N. Shukla, 2023, Nature.

Anti‐melanoma effects of R24, a monoclonal antibody against GD3 ganglioside

A. Houghton, P. Chapman, Philip S. Livingston, 1997, Melanoma research.

Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy

R. Sullivan, Melissa L. Johnson, M. Opyrchal, 2019, Clinical Trials.

ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.

E. Schmidt, Melissa L. Johnson, M. Opyrchal, 2017 .

A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).

R. Burger, R. Wenham, U. Matulonis, 2019, Journal of Clinical Oncology.

784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS

E. Basch, C. Cleeland, C. Logothetis, 2013 .

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

D. Slamon, J. O’Shaughnessy, P. Ordentlich, 2020 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.

A. Houghton, P. Chapman, Philip S. Livingston, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.